文献速递MDS 与骨髓增殖性肿瘤白血病

骨髓增生异常综合征重叠疾病及其诊断边界

MDS overlap disorders and diagnostic boundaries.
PubMed 文献 · Blood · 2019-01-22

本文综述骨髓增生异常综合征(MDS)与MDS/MPN、继发性急性髓系白血病、意义未明克隆性造血、意义未明克隆性血细胞减少及再生障碍性贫血之间的诊断边界,指出这些边界具有人为性,遗传学方法有助于更准确界定。

要点

  • MDS与相关髓系疾病的诊断边界常为人为划分,未必反映疾病生物学或结局。
  • MDS/MPN以造血发育异常伴单核、中性粒细胞或血小板增殖为特征,突变谱可区分其与相似疾病。
  • MDS与继发性急性髓系白血病的边界为人为定义且多年间被重新界定,遗传学研究显示继发性急性髓系白血病克隆可早于临床进展数月。

核心结论

  • MDS与相关髓系疾病之间的诊断边界可以是人为的,不一定反映 underlying 疾病生物学或结局。
  • 遗传学方法可能有助于更好地界定MDS与MDS/MPN、继发性急性髓系白血病、意义未明克隆性造血、意义未明克隆性血细胞减少及再生障碍性贫血之间的诊断边界。

研究设计与样本

  • 本文为综述,描述MDS与MDS/MPN、继发性急性髓系白血病、意义未明克隆性造血、意义未明克隆性血细胞减少及再生障碍性贫血之间的诊断边界及遗传学方法的作用。

主要发现

  • MDS/MPN以造血发育异常伴单核细胞、中性粒细胞或血小板增殖为特征,其突变谱可区分其与相似疾病并反映病理生理的重要差异。
  • 再生障碍性贫血与低增生性MDS在全血细胞减少和骨髓低增生患者中难以区分,遗传学特征可帮助识别预后和进展风险的差异。
  • MDS与继发性急性髓系白血病的边界为人为定义且多年来被重新界定,遗传学研究显示继发性急性髓系白血病克隆可早于MDS临床进展数月。
  • MDS伴原始细胞增多可被视为发育异常性骨髓衰竭综合征与寡原始细胞白血病之间的重叠。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myelodysplastic syndromes (MDS) are clonal diseases defined by clinical, morphologic, and genetic features often shared by related myeloid disorders. The diagnostic boundaries between these diseases can be arbitrary and not necessarily reflective of underlying disease biology or outcomes. In practice, measures that distinguish MDS from related disorders may be difficult to quantify and can vary as disease progression occurs. Patients may harbor findings that are not consistent with a single diagnostic category. Several overlap disorders have been formally described, such as the myelodysplastic/myeloproliferative neoplasms (MDS/MPNs). These disorders are characterized by hematopoietic dysplasia with increased proliferation of monocytes, neutrophils, or platelets. They may have mutational profiles that distinguish them from the disorders they resemble and reflect important differences in pathophysiology. MDS also shares diagnostic borders with other diseases. For example, aplastic anemia and hypoplastic MDS can be difficult to distinguish in patients with pancytopenia and bone marrow hypocellularity. Genetic features may help in this regard, because they can identify differences in prognosis and risk of progression. The boundary between MDS and secondary acute myeloid leukemia (sAML) is arbitrarily defined and has been redefined over the years. Genetic studies have demonstrated that sAML clones can precede clinical progression from MDS by many months, suggesting that MDS with excess blasts could be viewed as an overlap between a dysplastic bone marrow failure syndrome and an oligoblastic leukemia. This review will describe the diagnostic boundaries between MDS, MDS/MPNs, sAML, clonal hematopoiesis of indeterminate potential, clonal cytopenia of undetermined significance, and aplastic anemia and how genetic approaches may help to better define them.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Tanaka TN, Bejar R. MDS overlap disorders and diagnostic boundaries. Blood. 2019. PMID: 30670443. doi:10.1182/blood-2018-10-844670

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。